p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study

Journal of the National Cancer Institute

Volumn 95, Issue 13, 2003, Pages 961-970

  Ahrendt, Steven A ^a   Hu, Yingchuan ^a   Buta, Martin ^b   McDermott, Michael P ^c   Benoit, Nicole ^b   Yang, Stephen C ^b   Wu, Li ^b   Sidransky, David ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; PROTEIN P53;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BRONCHUS TUMOR; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; WILD TYPE;

EID: 0042964835     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.13.961     Document Type: Article

References (54)

1. Cancer: basic facts. Cancer facts and figures 2001. American Cancer Society; 2001. p. 2-11.
2. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 1991;83:1142-8.
3. Tobacco use. Cancer facts and figures 2001. American Cancer Society; 2001. p. 29-32.
4. National Center for Health Statistics (NCHS). Health, United States, 2000 with Adolescent Health Chartbook. Hyattsville (MD): NCHS; 2000.
5. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85.
6. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CE, Esteller M, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early-stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
7. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
8. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
9. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumor and bodily fluids. Science 2000;287:2017-9.
10. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, et al. Cigarette smoking and alcohol consumption increase the frequency of p53 gene mutations in non-small cell lung cancer. Cancer Res 2000;60:3155-9.
11. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000;6:1031-7.
12. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
13. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
14. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997;75:1125-30.
15. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999;18:1007-14.
16. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shrakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993;85:2018-23.
17. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, et al. p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effects on patient survival. Ann Oncol 1995;6:S9-S13.
18. de Anta JM, Jassem E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997;15:2951-8.
19. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106;(6 Suppl): 377S-81S.
20. Sioris T, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Kannio A, Salo JA, et al. Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure. Int J Cancer 2000;86:590-4.
21. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001;19:448-57.
22. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998;16:2469-77.
23. Top B, Mooi W, Klaver S, Boerrigter L, Wisman P, Elbers H, et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int J Cancer 1995;64:83-91.
24. Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, et al. Rapid p53 sequence analysis using an oligonucleotide probe array in primary lung cancer. Proc Natl Acad Sci U S A 1999;96:7382-7.
25. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:123-36.
26. Sidransky D, Von Eschenbach A, Tsai Y, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
27. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York (NY): Wiley; 1980.
28. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
29. Borresen AL, Anderson TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-5.
30. Meier P, Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology defined carcinogens. Cancer Res 1994;54:4855-78.
32. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-2.
33. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-11.
34. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
35. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban HR, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
36. Grafstrom RC, Dybukt JM, Sundqvist K, Atzori L, Nielson I, Curren RD, et al. Pathobiological effects of acetaldehyde in cultured human epithelial cells and fibroblasts. Carcinogenesis 1994;15:985-90.
37. Barnes SL, Singletary KW, Frey R. Ethanol and acetaldehyde enhance benzo[a]pyrene-DNA adduct formation in human mammary epithelial cells. Carcinogenesis 2000;21:2123-8.
38. Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001;61:8113-7.
39. Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS, et al. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 1999;12:54-60.
40. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, et al. Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001;60:176-88.
41. Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000;60:2716-22.
42. Wikman FP, Lu ML, Thykjaer T, Olesen SH, Andersen LD, Cordon-Cardo C, et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 2000;46:1555-61.
43. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-72.
44. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
45. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-8.
46. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-72.
47. Bullock A, Henckel J, Fersht A. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56.
48. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1990;1:571-80.
49. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60:6788-93.
50. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000;89:769-73.
51. Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001;92:386-94.
52. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
53. DaCosta L, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proc Natl Acad Sci U S A 1996;93:4192-6.
54. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.